News
1d
Zacks Investment Research on MSNNovo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US HurdlesNovo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the ...
Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $4.03 billion. On a per-share basis, the Bagsvaerd, ...
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
3d
Zacks Investment Research on MSNNovo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks ...
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...
Novo Nordisk also released its second quarter results this week, boasting profit of more than $4 billion. Per-share earnings ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results